【摘要】 通过文献回顾,详细描述单胺氧化酶-B抑制剂司来吉兰的研究历史、化学结构、药动学及临床研究的进展,并从多方面阐述其安全性。司来吉兰10 mg·d-1单药治疗能改善早期帕金森病(PD)患者的运动徐缓/少动症状,延迟左旋多巴的应用,延迟疾病的进展。司来吉兰与左旋多巴合用可改善晚期PD患者症状,减少左旋多巴服药次数和剂量,改善和减少与左旋多巴剂量相关的症状波动。除PD外,研究发现司来吉兰能有效治疗儿童和成人的注意力缺陷多动症;改善阿尔茨海默病和额颞痴呆患者的认知功能和日常生活能力;减少发作性睡病的突发睡眠次数;减少睡眠中周期性肢体运动的肌阵挛发作次数;有效治疗PD伴发抑郁,且对戒烟有帮助。司来吉兰的治疗剂量安全性佳。更多还原

【Abstract】 This is a review of literature on the selegiline used in Parkinson’s disease(PD).By the early 1960s,Knoll and colleagues developed a methamphetamine derivative(E-250),later named deprenyl that was developed L-deprenyl,now referred to as selegiline.The pharmacokinetic properties of selegiline,the chemical structure and the safety were reviewed.The use of selegiline 10 mg.d-1 of monotherapy in early PD was demonstrated a symptomatic benefit,a reduction in disability,a delay in the use of L-dopa therapy and a delay on disease progression.Selegiline is used in combination with L-dopa in more advanced disease and may suggest that reduced the end-of-dose motor fluctuation,and also lead to the reduction of dose and frequency of L-dopa require.Some clinical trial data may indeed suggest that selegiline be clinical effects in the treatment of adults and children with attention deficit hyperactivity disorders,and in the therapy of Alzheimer’s disease,fronto-temporal dementia,narcolepsy,periodic limb movements,depression associated with PD,cigarette addition.Selegiline is well tolerated with therapy dosage and its mortality with the drug has not been borne out by subsequent robust meta-analysis.更多还原